Cargando…
Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection
The aim of this work was to develop and validate an algorithm to monitor rates of, and response to, treatment of patients infected with hepatitis C virus (HCV) across England using routine laboratory HCV RNA testing data. HCV testing activity between January 2002 and December 2011 was extracted from...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4258076/ https://www.ncbi.nlm.nih.gov/pubmed/24214920 http://dx.doi.org/10.1002/hep.26926 |
_version_ | 1782347841711112192 |
---|---|
author | Lattimore, Sam Irving, Will Collins, Sarah Penman, Celia Ramsay, Mary on Behalf of the Collaboration for the Sentinel Surveillance of Blood-Borne Virus Testing, |
author_facet | Lattimore, Sam Irving, Will Collins, Sarah Penman, Celia Ramsay, Mary on Behalf of the Collaboration for the Sentinel Surveillance of Blood-Borne Virus Testing, |
author_sort | Lattimore, Sam |
collection | PubMed |
description | The aim of this work was to develop and validate an algorithm to monitor rates of, and response to, treatment of patients infected with hepatitis C virus (HCV) across England using routine laboratory HCV RNA testing data. HCV testing activity between January 2002 and December 2011 was extracted from the local laboratory information systems of a sentinel network of 23 laboratories across England. An algorithm based on frequency of HCV RNA testing within a defined time period was designed to identify treated patients. Validation of the algorithm was undertaken for one center by comparison with treatment data recorded in a clinical database managed by the Trent HCV Study Group. In total, 267,887 HCV RNA test results from 100,640 individuals were extracted. Of these, 78.9% (79,360) tested positive for viral RNA, indicating an active infection, 20.8% (16,538) of whom had a repeat pattern of HCV RNA testing suggestive of treatment monitoring. Annual numbers of individuals treated increased rapidly from 468 in 2002 to 3,295 in 2009, but decreased to 3,110 in 2010. Approximately two thirds (63.3%; 10,468) of those treated had results consistent with a sustained virological response, including 55.3% and 67.1% of those with a genotype 1 and non-1 virus, respectively. Validation against the Trent clinical database demonstrated that the algorithm was 95% sensitive and 93% specific in detecting treatment and 100% sensitive and 93% specific for detecting treatment outcome. Conclusions: Laboratory testing activity, collected through a sentinel surveillance program, has enabled the first country-wide analysis of treatment and response among HCV-infected individuals. Our approach provides a sensitive, robust, and sustainable method for monitoring service provision across England. (Hepatology 2014;59:1343-1350) |
format | Online Article Text |
id | pubmed-4258076 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BlackWell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-42580762014-12-11 Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection Lattimore, Sam Irving, Will Collins, Sarah Penman, Celia Ramsay, Mary on Behalf of the Collaboration for the Sentinel Surveillance of Blood-Borne Virus Testing, Hepatology Viral Hepatitis The aim of this work was to develop and validate an algorithm to monitor rates of, and response to, treatment of patients infected with hepatitis C virus (HCV) across England using routine laboratory HCV RNA testing data. HCV testing activity between January 2002 and December 2011 was extracted from the local laboratory information systems of a sentinel network of 23 laboratories across England. An algorithm based on frequency of HCV RNA testing within a defined time period was designed to identify treated patients. Validation of the algorithm was undertaken for one center by comparison with treatment data recorded in a clinical database managed by the Trent HCV Study Group. In total, 267,887 HCV RNA test results from 100,640 individuals were extracted. Of these, 78.9% (79,360) tested positive for viral RNA, indicating an active infection, 20.8% (16,538) of whom had a repeat pattern of HCV RNA testing suggestive of treatment monitoring. Annual numbers of individuals treated increased rapidly from 468 in 2002 to 3,295 in 2009, but decreased to 3,110 in 2010. Approximately two thirds (63.3%; 10,468) of those treated had results consistent with a sustained virological response, including 55.3% and 67.1% of those with a genotype 1 and non-1 virus, respectively. Validation against the Trent clinical database demonstrated that the algorithm was 95% sensitive and 93% specific in detecting treatment and 100% sensitive and 93% specific for detecting treatment outcome. Conclusions: Laboratory testing activity, collected through a sentinel surveillance program, has enabled the first country-wide analysis of treatment and response among HCV-infected individuals. Our approach provides a sensitive, robust, and sustainable method for monitoring service provision across England. (Hepatology 2014;59:1343-1350) BlackWell Publishing Ltd 2014-04 2014-02-28 /pmc/articles/PMC4258076/ /pubmed/24214920 http://dx.doi.org/10.1002/hep.26926 Text en Copyright © 2013 The Authors. Hepatology published by Wiley on behalf of the American Association for the Study of Liver Diseases. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Viral Hepatitis Lattimore, Sam Irving, Will Collins, Sarah Penman, Celia Ramsay, Mary on Behalf of the Collaboration for the Sentinel Surveillance of Blood-Borne Virus Testing, Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection |
title | Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection |
title_full | Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection |
title_fullStr | Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection |
title_full_unstemmed | Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection |
title_short | Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection |
title_sort | using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis c virus infection |
topic | Viral Hepatitis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4258076/ https://www.ncbi.nlm.nih.gov/pubmed/24214920 http://dx.doi.org/10.1002/hep.26926 |
work_keys_str_mv | AT lattimoresam usingsurveillancedatatodeterminetreatmentratesandoutcomesforpatientswithchronichepatitiscvirusinfection AT irvingwill usingsurveillancedatatodeterminetreatmentratesandoutcomesforpatientswithchronichepatitiscvirusinfection AT collinssarah usingsurveillancedatatodeterminetreatmentratesandoutcomesforpatientswithchronichepatitiscvirusinfection AT penmancelia usingsurveillancedatatodeterminetreatmentratesandoutcomesforpatientswithchronichepatitiscvirusinfection AT ramsaymary usingsurveillancedatatodeterminetreatmentratesandoutcomesforpatientswithchronichepatitiscvirusinfection AT onbehalfofthecollaborationforthesentinelsurveillanceofbloodbornevirustesting usingsurveillancedatatodeterminetreatmentratesandoutcomesforpatientswithchronichepatitiscvirusinfection |